Loading…
Proceeds to advance first-in-class treatment for SYNGAP1-related disorders.
CAMP4 Therapeutics Corporation announced on 2025-09-10 CAMP4 Therapeutics Corporation announced an oversubscribed private placement of up to $100 million to advance the first-in-class treatment for SYNGAP1-related disorders.
The announcement cited $100 million, $50 million, 26,681,053 shares, $1.53 per share, 36,361 shares, $1.65 per share, 6,003,758 pre-funded warrants, and $1.5299 per pre-funded warrant. Share consideration (payable in the issuer's shares): 26,681,053 shares.
CAMP4 Therapeutics Corporation Common Stock has a free float of 22,796,000 shares and 46,881,100 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.